-
May 2021
The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetes.
Immunol Cell BiolWiedeman AE, Speake C, Long SA -
Apr 2021
Combination therapy in recent-onset type 1 diabetes.
Lancet Diabetes EndocrinolLong SA, Speake C -
Mar 2021
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
Sci Transl MedSims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC, Type 1 Diabetes TrialNet Study Group. -
Feb 2021
Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.
JCI InsightDiggins KE, Serti E, Muir V, Rosasco M, Lu T, Balmas E, Nepom GT, Long SA, Linsley PS -
Feb 2021
The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity.
J Clin InvestBolouri H, Speake C, Skibinski D, Long SA, Hocking AM, Campbell DJ, Hamerman JA, Malhotra U, Buckner JH, Benaroya Research Institute COVID-19 Research Team. -
Jan 2021
Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice.
DiabetologiaNagy N, Kaber G, Kratochvil MJ, Kuipers HF, Ruppert SM, Yadava K, Yang J, Heilshorn SC, Long SA, Pugliese A, Bollyky PL -
Oct 2020
A distinct GM-CSF+ T helper cell subset requires T-bet to adopt a TH1 phenotype and promote neuroinflammation.
Sci ImmunolRasouli J, Casella G, Yoshimura S, Zhang W, Xiao D, Garifallou J, Gonzalez MV, Wiedeman A, Kus A, Mari ER, Fortina P, Hakonarson H, Long SA, Zhang GX, Ciric B, Rostami A -
Jan 2020
Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression.
J Clin InvestWiedeman AE, Muir VS, Rosasco MG, DeBerg HA, Presnell S, Haas B, Dufort MJ, Speake C, Greenbaum CJ, Serti E, Nepom GT, Blahnik G, Kus AM, James EA, Linsley PS, Long SA -
Jan 2020
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.
Diabetes CareBattaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M -
Dec 2019
Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells.
J ImmunolAnderson W, Thorpe J, Long SA, Rawlings DJ -
Dec 2019
A composite immune signature parallels disease progression across T1D subjects.
JCI InsightSpeake C, Skinner SO, Berel D, Whalen E, Dufort MJ, Young WC, Odegard JM, Pesenacker AM, Gorus FK, James EA, Levings MK, Linsley PS, Akirav EM, Pugliese A, Hessner MJ, Nepom GT, Gottardo R, Long SA -
Aug 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
N Engl J MedHerold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. -
Aug 2019
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D.
Curr Opin Endocrinol Diabetes ObesLinsley PS, Long SA -
Jul 2019
Human CD4+CD103+ cutaneous resident memory T cells are found in the circulation of healthy individuals.
Sci ImmunolKlicznik MM, Morawski PA, Höllbacher B, Varkhande SR, Motley SJ, Kuri-Cervantes L, Goodwin E, Rosenblum MD, Long SA, Brachtl G, Duhen T, Betts MR, Campbell DJ, Gratz IK -
Jul 2019
Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.
DiabetesAhmed S, Cerosaletti K, James EA, Long SA, Mannering SI, Speake C, Nakayama M, Tree T, Roep BO, Herold KC, Brusko TM